Matinas Biopharma Holdings, Inc
1.3400-0.11 (-7.71%)
Oct 29, 4:00:00 PM EDT · NYSE American · MTNB · USD
Key Stats
Market Cap
7.44MP/E (TTM)
-Basic EPS (TTM)
-3.87Dividend Yield
0%Recent Filings
8-K
Warrant exchange simplifies structure
Matinas BioPharma Holdings exchanged warrants to purchase 466,666 shares of common stock—issued April 5, 2024, at a $17.50 exercise price—for an equal number of unrestricted shares on August 15, 2025, under Section 3(a)(9) exemption. This cancels the warrants outright. Deal simplifies capital structure. No cash changed hands.
10-Q
Q2 FY2025 results
Matinas BioPharma narrowed its Q2 operating loss to $1.8M from $5.8M a year earlier, thanks to slashed R&D spending that dropped to zero amid a paused MAT2203 program and headcount cuts, while G&A fell 25% y/y on lower stock-based comp. For the half-year, operating loss improved to $3.8M from $11.7M, but net loss widened to $6.9M from $11.5M due to a $3.2M hit from fair-value changes on warrants reclassified to equity in June. Cash burn eased to $4.0M from $8.9M, bolstered by $3.3M from a preferred stock raise in February and April closings for $3.3M (cash, convertible to 5.6M shares with warrants for 11.3M more). Quarter-end cash stood at $6.5M, with $2.5M in operating lease liabilities maturing through 2029. No free cash flow disclosed in the 10-Q. Yet funding remains tight.
8-K
Authorized shares doubled
Matinas BioPharma Holdings doubled its authorized common stock to 500 million shares via a Certificate of Amendment filed August 6, 2025, following stockholder approval on June 23. This boosts flexibility for potential equity raises in biotech development. Yet the move signals dilution risks for existing holders.
8-K
2025 Plan approved
Matinas BioPharma stockholders approved the 2025 Equity Incentive Plan at the June 23 annual meeting, effective immediately after board approval on April 30. The plan authorizes 763,048 shares for options, restricted stock, and performance awards to align employee incentives with company success. Yet broker non-votes hit 1.8 million shares. This bolsters talent retention amid biotech volatility.
10-Q
Q1 FY2025 results
Matinas BioPharma narrowed its Q1 operating loss to $1.9M from $5.9M a year earlier, driven by slashed R&D spending to $85K amid a paused MAT2203 program and headcount cuts, while G&A dipped to $1.9M on lower stock-based comp. Net loss improved to $1.7M, or $(0.33) per share, from $5.8M or $(1.34), with the quarter's figure aligning against 5.1M diluted shares; a $294K gain from warrant liability fair-value changes cushioned the bottom line, yet other expenses edged up slightly. Cash burn eased to $2.0M from $5.8M, leaving $6.9M in cash equivalents at quarter-end, bolstered by $1.6M net from a preferred stock raise—though a second $1.5M tranche closed in April. No debt burdens, but leases loom at $2.7M present value. The February private placement, issuing 1,650 Series C shares for $1.65M (cash) and warrants (5-year term, $0.64 strike), locks out further equity issuances until November. Cash won't last the year without partners. Clinical trial delays could stall MAT2203 progress.
IPO
Employees
Sector
Industry
IMA
ImageneBio, Inc.
8.79+0.09
IMUC
EOM Pharmaceutical Holdings Inc
0.18+0.00
LIANY
LianBio
0.07+0.00
MAIA
MAIA Biotechnology, Inc.
1.30-0.10
MBIO
Mustang Bio, Inc.
1.47-0.03
MRNA
Moderna, Inc.
24.70-0.65
NBTX
Nanobiotix S.A.
17.99+0.36
NNVC
NanoViricides, Inc.
1.86+0.33
NVCT
Nuvectis Pharma, Inc.
6.77+0.34
OMER
Omeros Corporation
7.68-0.28